Working with MRC to give UK academia access to AstraZeneca compounds

In 2011, a landmark agreement between MRC and AstraZeneca gave UK academic researchers unprecedented access to 22 of our compounds. These compounds had stalled in early testing, often because they didn’t prove effective against the original target. But they may still be useful against other diseases.